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Background
Atrial natriuretic peptide (ANP) is released into the circu-
lation by right atrial stretch and increases systemic vascu-
lar permeability through activation of natriuretic peptide
receptor A (NPR-A) and generation of cGMP by particu-
late guanylate cylase.
Materials and methods
The NPR-A antagonist anantin was utilized in an in vivo
mouse model of unilateral left lung IR (30 min:150 min),
and pulmonary vascular permeability was assessed by
Evans blue dye (EBD)-labeled albumin escape. The NPR-
A signalling cascade was assessed by measurements of cir-
culating and lung tissue levels of ANP, cGMP and phos-
phorylation of lung vasodilator-stimulated
phosphoprotein (VASP). Additionally the effect of exoge-
nous ANP administration on capillary filtration coeffi-
cient was determined in an in situ isolated perfused
mouse model of lung IR.
Results
In spontaneously breathing mice, left lung IR increased
EBD protein extravasation in the reperfused left lung com-
pared to the unmanipulated right lung (left lung/right
lung EBD = 2.3 ± 0.08; RL = 0.06 ± 0.00 AU, n = 8). Anan-
tin attenuated this (left lung/right lung EBD = 1.69 ± 0.03,
RL = 0.06 ± 0.00 AU, n = 8). Compared to control mice (n
= 7), left pulmonary artery occlusion resulted in: a) a 10-
fold increase (P < 0.05) in circulating ANP levels at 0 and
15 min of reperfusion; b) a 2-fold increase (P < 0.01) in
left lung tissue cGMP content at 60 min of reperfusion (n
= 6–7); c) no change in circulating or right lung cGMP
concentrations; d) increased lung tissue expression of
VASP phosphorylated at ser235 (the PKGI-preferred site)
at 150 min of reperfusion (P < 0.05); e) no change in
ser153 phosphorylation (the PKA-preferred site). Anantin
treatment: a) further elevated circulating ANP levels; b)
blocked the increase in tissue cGMP levels in the left lung;
c) significantly decreased circulating cGMP at 60 min and
ser235 VASP phosphorylation at 150 min (n = 4–12); d)
had no effect on circulating or lung tissue cAMP. In the in
situ lung IR preparation (30 min:60 min), ANP adminis-
tration with reperfusion (2.5 nM) significantly increased
capillary filtration coefficient (Kf) compared to diluent
(4.3 ± 2.1 vs. 2.2 ± 0.7 g/min/mmHg/100 g WW; n = 5–7).
Conclusion
These data suggest that NPR-A stimulation by ANP con-
tributes to pulmonary vascular injury following lung IR.
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